APUS (Apimeds Pharmaceuticals Us) Interest Expense: $-1.10 Mil (TTM As of Mar. 2026)


APUS Apimeds Pharmaceuticals Us Inc APUS
14 GF Score
Price $0.72
! 3 Warning Signs
View Full Analysis

What is Apimeds Pharmaceuticals Us Interest Expense?

Apimeds Pharmaceuticals Us APUS -2.04% 14 Interest Expense is $-1.10 Mil as of Mar. 2026. GuruFocus rates APUS with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Apimeds Pharmaceuticals Us's interest expense for the three months ended in Mar. 2026 was $ -0.86 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-1.10 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Apimeds Pharmaceuticals Us's Operating Income for the three months ended in Mar. 2026 was $ -12.19 Mil. Apimeds Pharmaceuticals Us's Interest Expense for the three months ended in Mar. 2026 was $ -0.86 Mil. Apimeds Pharmaceuticals Us did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Apimeds Pharmaceuticals Us  (AMEX:APUS) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Apimeds Pharmaceuticals Us's Interest Expense for the three months ended in Mar. 2026 was $-0.86 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-12.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.12 Mil.

Apimeds Pharmaceuticals Us's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Apimeds Pharmaceuticals Us did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Apimeds Pharmaceuticals Us Interest Expense Historical Data

* Premium members only.

The historical data trend for Apimeds Pharmaceuticals Us's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apimeds Pharmaceuticals Us Interest Expense Chart

Apimeds Pharmaceuticals Us Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.01 -0.03 -0.04 -0.12 -0.28

Apimeds Pharmaceuticals Us Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.02 -0.01 -0.22 -0.86
APUS
14GF Score
Apimeds Pharmaceuticals Us Inc APUS
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apimeds Pharmaceuticals Us Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-1.10 Mil mean?
Apimeds Pharmaceuticals Us (APUS) has a Interest Expense of $-1.10 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Apimeds Pharmaceuticals Us and its competitors.
Is Apimeds Pharmaceuticals Us' Interest Expense too high?
Apimeds Pharmaceuticals Us' current Interest Expense is $-1.10 Mil. Overall, Apimeds Pharmaceuticals Us has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Apimeds Pharmaceuticals Us' Interest Expense compare to KAYS and BIOE?
Apimeds Pharmaceuticals Us' Interest Expense of $-1.10 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Apimeds Pharmaceuticals Us and its competitors. Apimeds Pharmaceuticals Us's current Interest Expense is $-1.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apimeds Pharmaceuticals Us stock overvalued right now?
Apimeds Pharmaceuticals Us (APUS) has a current Interest Expense of $-1.10 Mil. The current Interest Expense is $-1.10 Mil. Apimeds Pharmaceuticals Us' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Apimeds Pharmaceuticals Us (APUS), the current Interest Expense is $-1.10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apimeds Pharmaceuticals Us Business Description

Address 100 Matawan Road, Suite 325, Matawan, NJ, USA, 07747
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
14GF Score

Get the complete analysis for APUS

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.72
Price